1. Pink Sheet
  2. >>Compliance

J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions

 
• By Eileen Francis

J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.

Johnson & Johnson has three buyers in its latest consumer health product divestment. Rights to its 1% ketoconazole anti-dandruff shampoo, branded Nizatrol A-D in the US, are going to a separate firm for each of the US-Latin America, Asia-Pacific and Europe-Middle East-Africa regions.

J&J’s Belgian pharma division, Janssen Pharmaceutica NV, is selling US and Latin American rights to the formulation to Kramer Laboratories Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance